MDACC Study No:2012-1180 ( NCT No: NCT01297543)
Title:A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:CLT-008; G-CSF
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn about the safety of giving
CLT-008 to patients receiving chemotherapy for leukemia or MDS.

CLT-008 is made from the blood cells of healthy donors. It is designed to
temporarily replace a type of your white blood cells, which may help lower the
risk of infection while your white blood cell count is low (usually about 2-3
weeks after chemotherapy).

Neupogen® (filgrastim, G-CSF) is designed to help lower the risk of infection
by increasing your white blood cell count.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:CLT-008
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Cellerant Therapeutics, Inc. or designee
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults